Business Context and Reporting Period
Company: Drugs Made In America Acquisition II Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2026
Reporting Period: Events occurring between March 5, 2026, and March 11, 2026.
Context: The Company, a Cayman Islands-based Special Purpose Acquisition Company (SPAC), is in the process of securing financing to support its initial business combination. It is classified as an emerging growth company.
Key Financial Metrics and Obligations
- Bridge Loan Issued: $150,000 unsecured convertible note issued to Alpha MultiFamily Office on March 11, 2026.
- Contemplated Total Financing: $1,400,000 via Convertible Notes Financing.
- Remaining Funding: $1,250,000 pending execution of definitive documentation.
- Interest Rate: 0% (The Bridge Note does not bear interest).
- Maturity Date: Nine months from issuance (approximately December 2026), unless earlier converted.
- Conversion Terms: Upon consummation of the Business Combination, the note may be converted into shares of the combined entity at a 35% discount to the market price.
- Use of Proceeds: Accounting expenses, audit expenses, and other costs related to the Business Combination.
Material Changes and Events
The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation. Key developments include:
- Letter of Intent (LOI): Entered into on March 5, 2026, with Alpha MultiFamily Office for a proposed $1,400,000 financing.
- Addendum: Executed on March 9, 2026, amending economic terms of the LOI.
- Disbursement Schedule: The Addendum contemplates that an aggregate of $400,000 will be disbursed to the Company on or prior to March 30, 2026.
- Bridge Note Execution: The initial $150,000 tranche was funded on March 11, 2026, serving as the first payment under the LOI.
Outlook, Risks, and Contingencies
- Contingent Financing: The remaining $1,250,000 of the proposed financing is subject to the negotiation and execution of a definitive convertible note purchase agreement.
- Conversion Risk: The 35% discount conversion feature may result in significant dilution to existing shareholders upon the Business Combination.
- Operational Status: The Company is pre-revenue and currently incurring expenses related to the search for and execution of a business combination.
- Management Commentary: The filing indicates the Company intends to use the proceeds strictly for transaction-related expenses (audit and accounting).
Investor Verification Checklist
- Verify the execution of the definitive Convertible Note Purchase Agreement for the remaining $1,250,000.
- Confirm the disbursement of the additional $250,000 required to meet the $400,000 aggregate funding target by March 30, 2026.
- Review the full text of the LOI (Exhibit 10.1), Addendum (Exhibit 10.2), and Bridge Note (Exhibit 10.3) for covenants not summarized in the 8-K.
- Assess the potential dilution impact of the 35% conversion discount on the Company's capital structure post-business combination.
- Monitor the Company's cash runway given the reliance on this financing for audit and accounting expenses.